Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC

The study is a multicenter, open-label, phase II clinical study, and the purpose of the study is to explore the complete response rate (CR, Defined as pathological complete response (pCR) + Clinical complete response (cCR)) of patients with RAS/BRAF wild type locally advanced rectal cancer(LARC) treated with short-term radiotherapy, sequential HLX07, Serplulimab and CAPOX. A total of 29 patients were included in this study.

Trial Details

NCT ID
NCT06542588
Phase
PHASE2
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody)
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667
  • Wuhan, Hubei, China|30.58333,114.26667
  • Hubei, China|29.08114,120.41732

Key Eligibility Criteria

  • Patients or their family members agree to participate in the study and sign the informed consent form;
  • Age 18-75 years, male or female;
  • Histologically confirmed Locally Advanced rectal adenocarcinoma
  • Genetic test and/or immunohistochemical confirmation of RAS, BRAF wild type

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →